|Over a quarter ago|
Seadrill Partners announces suspension of trading from NYSE » 09:2009/0609/06/19
Seadrill Partners has…
Seadrill Partners has received notification from The New York Stock Exchange that trading in the Company's common units has been suspended and proceedings to delist the Company's common units have commenced. The NYSE reached its decision due to the Company's low market capitalization pursuant to Section 802.01B of the NYSE's Listed Company Manual. The Company expects its common units to trade in the over the counter market beginning on September 6, 2019 under the ticker symbol "SDLPF". The transition to the OTC market is not expected to affect business operations and the Company will continue to file periodic reports with the U.S. Securities and Exchange Commission under applicable federal securities laws. The Company intends to appeal this delisting determination. During the appeal process, its common units are expected to continue to trade in the OTC market. Delisting procedures will be suspended pending the outcome of the appeal.
Seven new option listings and two option delistings on September 6th » 08:3009/0609/06/19
CATB, EVFM, TCRR, XPEL, YCBD, CCIH, SDLP
New option listings for…
New option listings for September 6th include Catabasis Pharmaceuticals (CATB), ChinaCache International Holdings Ltd (ADS) (CCIHY), Evofem Biosciences Inc (EVFM), Seadrill Partners LLC (SDLPF), TCR2 Therapeutics Inc (TCRR), XPEL Inc (XPEL), and cbdMD Inc (YCBD). Option delistings effective September 6th include ChinaCache International Holdings Ltd (ADS) (CCIH) and Seadrill Partners LLC (Units) (SDLP).
Seadrill Partners trading halted, news pending 16:0509/0409/04/19